In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From FMC BioPolymer

Start-Up News

Noteworthy news from medtech start-ups. This month we profile CardioPolymers Inc., which is developing a highly purified form of seaweed that, when implanted into the heart, has the potential to stop or even reverse the progression of congestive heart failure. We also profile Aura Medsystems, which is developing photodynamic soft-tissue repair technology.

Medical Device

TheraCardia Inc.

Having focused largely on the drug component of drug-eluting stents, most companies developing the next wave of bioabsorbable stents are working with the same biopolymers. Theracardia, however, begins life with a portfolio of novel biopolymers that inherently have the potential to avoid inflammation in the body, are bioabsorbable and can be engineered to achieve specific biological effects. The company is validating its platform in a stent biocoating in preparation for developing its own improved bioabsorbable stent, one that, it hopes, will promote rapid endothelialization and reduce restenosis without incorporating a drug.

Start-Up News September 2007

TheraCardia has a portfolio of natural biopolymers that it will develop for stents; initially, for stent coatings, and soon, a bioabsorbable stent that avoids inflammation and contributes to endothelization, without the need for a drug. Surgeon-founded Aragon Surgical will develop a platform of products to make surgeries faster and safer. Intelect Medical is developing new neurostimulation devices that, it believes, offer advances over the devices of predecessors. It's initial target application is traumatic brain injury.

Platform Technologies

Recent Dealmaking (04/2004)

Summarizing the month in European dealmaking.

See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register